BioSpace News Archive

Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT® study presented by Benjamin E. Peterson, M.D., Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions, showed that administration of 4 g/day of VASCEPA

We are thrilled to be collaborating with Noga to accelerate and enable bringing a novel autologous gene therapy for PIDs to the clinic and patients. This collaboration will be the first instance of harnessing the Cocoon platform to manufacture an autologous gene therapy, thus showcasing the flexibility of the Cocoon system.

Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction

In a world of uncertainty, one thing is for sure — cancer doesn’t stop during a global crisis.

Doctors and researchers from across Northwell Health’s New York-based hospitals saw an “alarming number” of hospitalized coronavirus disease 2019 patients develop acute kidney injury during the height of the pandemic – rates higher than reported from China, according to new data published in Kidney International, the official journal of the International Society of Nephrology.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced the initiation of patient dosing in a Phase 1 dose escalation study evaluating XMT-1592, its Dolasynthen ADC targeting NaPi2b.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced first quarter 2020 financial results and provided an operational update.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, May 21, 2020.

Announced positive preclinical data that validates the key advantages of the proprietary NeuBase peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the first quarter ended March 31, 2020 and provided an update on business progress.